Black/African American prostate cancer patients treated with

Black/African American patients with prostate cancer who were treated with the androgen receptor inhibitor darolutamide (Nubeqa) had clinical outcomes similar to those observed in the overall clinical trial population, according to results from the ARAMIS phase III clinical trial presented at the 14th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved, held online October 6-8, 2021.

Related Keywords

Boston , Massachusetts , United States , American , Astellas Pharma , Orion Pharma , Bristol Myers Squibb Sanofi , Bristol Myers Squibb , Medivation Astellas , Emily Henderson , Amgen , Foundation Medicine , Bayer Ag , Ferring Pharmaceuticals , Myovant Sciences , Carolina Urologic Research Center , Boston Scientific , Pfizer , Astrazeneca , Janssen Scientific Affairs , Tolmar Inc , African American , Cancer Health Disparities , Ethnic Minorities , Medically Underserved , Medical Director , Carolina Urologic Research , Bristol Myers , Clovis Oncology , Exact Imaging , Myriad Genetics , Propella Therapeutics , Sesen Bio , Androgen , Flood , Rain , Dancer , Central Nervous System , Chemotherapy , Clinical Trial , Efficacy , Enetics , Health Care , Health Disparities , Maging , Medicine , Metastasis , Ortality , Nervous System , Ncology , Placebo , Prostate , Prostate Cancer , Eceptor , Research ,